Last edition
News about "development strategy"
Astellas Pharma and Audax Biosciences Sign Exclusive Option and License Agreement for DAX-044
Audax Biosciences and Astellas Pharma partner to advance DAX-044, an investigational IL-12-based immunotherapy designed to concentrate immune activation within the tumour microenvironment.
Development Strategy | 29/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members